⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686925 | 0.63 | — | — | |
| SCHEMBL15382251 | 0.62 | — | — | |
| SCHEMBL690070 | 0.62 | — | — | |
| SCHEMBL29111914 | 0.61 | — | — | |
| SCHEMBL2094005 | 0.59 | — | — | |
| SCHEMBL6057257 | 0.57 | — | — | |
| SCHEMBL4082492 | 0.57 | — | — | |
| SCHEMBL4052966 | 0.57 | — | — | |
| SCHEMBL1686922 | 0.57 | — | — | |
| SCHEMBL1101984 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| CN-113874372-A | Novel oxadiazole compounds for controlling or preventing phytopathogenic fungi | PI工业有限公司 | 2021-12-31 | — | — | CN | claimed |
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | claimed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| EP-2951179-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | Merck Patent GmbH (DE) | 2015-12-09 | — | — | EP | claimed |
| CN-104955826-A | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH | 2015-09-30 | — | — | CN | claimed |
| WO-2014117920-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | WO | claimed |
| US-7977332-B2 | Insecticidal N-(heteroarylalkyl)alkanediamine derivatives | FMC CORPORATION (US) | 2011-07-12 | — | — | US | claimed |
| US-20110065710-A1 | Insecticidal N-(Heteroarylalkyl)Alkanediamine Derivatives | FMC CORPORATION | 2011-03-17 | — | — | US | claimed |
| WO-2008032060-A1 | 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERAZINYLPYRIMIDINE DERIVATIVES AS P13K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032033-A1 | 4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | claimed |
| US-20080051401-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PASS MARTIN | 2008-02-28 | — | — | US | claimed |
| CN-101048400-A | Insecticidal N, N-di (heteroarylalkyl) amine derivatives | BAYER CROPSCIENCE AG (DE) | 2007-10-03 | — | — | CN | claimed |
| CN-1889836-A | Insecticidal n-(heteroarylalkyl)alkanediamine derivatives | FMC CORP (US) | 2007-01-03 | — | — | CN | claimed |
| US-6458779-B1 | TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-01 | — | — | US | claimed |
| EP-0569333-B1 | Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids | NOVARTIS AG (CH) | 1999-01-07 | — | — | EP | claimed |
| US-5424441-A | Nootropic, antiepileptic agents | CIBA-GEIGY CORPORATION (US) | 1995-06-13 | — | — | US | claimed |
| EP-0569333-A2 | Novel N-aralkyl and N-heteroaralkylamino alcane phosphinic acids | CIBA-GEIGY AG (CH) | 1993-11-10 | — | — | EP | claimed |